Voronina Daria V, Vavilova Irina V, Zubkova Olga V, Ozharovskaia Tatiana A, Popova Olga, Chugunova Anastasia S, Goldovskaya Polina P, Zrelkin Denis I, Savina Daria M, Favorskaya Irina A, Shcheblyakov Dmitry V, Logunov Denis Y, Gintsburg Alexandr L
N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, Ministry of Health, Moscow 123098, Russia.
Viruses. 2025 Aug 5;17(8):1085. doi: 10.3390/v17081085.
Despite the widespread accessibility of vaccines and antivirals, seasonal influenza virus epidemics continue to pose a threat to public health. In this study, we constructed a recombinant replication-deficient simian adenovirus type 25 vector carrying the full-length hemagglutinin (HA) of the H1N1 influenza virus, named rSAd25-H1. Both systemic and mucosal humoral immune responses, as well as the protective efficacy, were assessed in mice immunized via the intramuscular (IM) or intranasal (IN) route. A single-dose IM or IN administration of rSAd25-H1 elicited a robust systemic IgG antibody response, including hemagglutination inhibition antibodies. As expected, only IN immunization was able to induce IgA production in serum and respiratory mucosa. Notably, a single dose of rSAd25-H1 at the highest dose (10 viral particles) conferred complete protection against lethal homologous H1N1 challenge in mice despite the route of administration. These findings demonstrate the potential of simian adenovirus type 25-based vectors as a promising candidate for intranasal vaccine development targeting respiratory pathogens.
尽管疫苗和抗病毒药物广泛可得，但季节性流感病毒流行仍继续对公众健康构成威胁。在本研究中，我们构建了一种重组的、复制缺陷型的25型猿猴腺病毒载体，其携带H1N1流感病毒的全长血凝素（HA），命名为rSAd25-H1。通过肌肉注射（IM）或鼻内（IN）途径免疫小鼠后，评估了全身和黏膜体液免疫反应以及保护效力。单剂量IM或IN给予rSAd25-H1引发了强烈的全身IgG抗体反应，包括血凝抑制抗体。正如预期的那样，只有鼻内免疫能够诱导血清和呼吸道黏膜产生IgA。值得注意的是，无论给药途径如何，单剂量最高剂量（10个病毒颗粒）的rSAd25-H1都能使小鼠完全抵御致死性同源H1N1攻击。这些发现证明了基于25型猿猴腺病毒的载体作为针对呼吸道病原体的鼻内疫苗开发的有前景候选物的潜力。
